Transgene Ownership
| TRGNF Stock | USD 1.59 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Transgene |
Transgene Pink Sheet Ownership Analysis
The company has price-to-book ratio of 0.02. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Transgene SA recorded a loss per share of 0.23. The entity had not issued any dividends in recent years. Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 143 people.The quote for Transgene SA is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Transgene SA contact Hedi Brahim at 33 3 88 27 91 00 or learn more at https://www.transgene.fr.Currently Active Assets on Macroaxis
Other Information on Investing in Transgene Pink Sheet
Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.